|Bid||0.0000 x 1800|
|Ask||3.7400 x 2900|
|Day's Range||2.5900 - 2.7537|
|52 Week Range||2.5900 - 10.2600|
|Beta (3Y Monthly)||1.73|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Bellicum Pharmaceuticals (BLCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bellicum Pharmaceuticals (BLCM) delivered earnings and revenue surprises of 1.79% and 158.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Bellicum Pharmaceuticals, Inc. - Common Stock (NASDAQ: BLCM ) announces its next round of earnings this Tuesday, March 12. Here's Benzinga's advanced look at Bellicum's Q4 earnings report. Earnings and ...
Building up an investment case requires looking at a stock holistically. Today I've chosen to put the spotlight on Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) due to its excellent fundamentals in more Read More...
Bellicum Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Jazz (JAZZ) announces that the FDA has extended the review period of its new drug application for sleep drug, solriamfetol, by three months to Mar 20, 2019.
Novan's (NOVN) nitric oxide candidate, SB206, demonstrates statistically significant reduction of lesions in patients with molluscum contagiosum.
Anyone researching Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and there Read More...
Bellicum Pharmaceuticals (BLCM) delivered earnings and revenue surprises of 3.51% and 349.23%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Bellicum Pharmaceuticals (BLCM) delivered earnings and revenue surprises of -5.26% and 376.32%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?